Nov 2 (Reuters) - Inovio Pharmaceuticals Inc :Inovio Pharmaceuticals says ‍on Oct 30, Apollobio board approved agreements of license & collaboration agreement with co which was announced on July 14.Inovio Pharmaceuticals - Approval ‍included amendment to the $35 million payment co to receive from Apollobio as per agreement agreed between co, Apollobio.Inovio Pharmaceuticals says amendment was to reduce the purchase price of the $35 million payment from $8.20 to $7.22 per share - SEC Filing​.
Full Article

Inovio Pharmaceuticals Inc : Inovio and Apollobio to collaborate on development and commercialization of hpv pre-cancer immunotherapy VGX-3100 in Greater China . Inovio Pharmaceuticals Inc - Inovio will receive $15 million in upfront and near term payments comprising an initial $3 million signing fee . Inovio Pharmaceuticals Inc - Inovio will receive a $12 million milestone upon lifting of VGX-3100 Phase 3 pre-initiation clinical hold by FDA . Inovio Pharmaceuticals Inc - under a separate equity agreement, Apollobio will invest in Inovio common stock subsequent to lifting of clinical hold . Inovio Pharmaceuticals Inc - aggregate investment, which is expected to be completed in first half of 2017, will not exceed $35 million . Inovio Pharmaceuticals Inc - Apollobio will fund all clinical development costs within licensed territory, and will pay Inovio up to $20 million . Inovio Pharma- agreements are subject to People's Republic of China corporate and regulatory approvals, payments are subject to PRC currency approvals .Inovio - payment of $20 million based upon achievement of certain regulatory milestones in U.S., China, Korea, double digit royalties on net sales of VGX-3100.
Full Article

Inovio Pharmaceuticals Inc : Inovio launches Zika vaccine trial in midst of Puerto Rico epidemic to explore early signals of vaccine efficacy . Expects to report results before end of this year .Is developing its Zika vaccine, GLS-5700, with Geneone Life Science, Inc. And academic collaborators from US and Canada.
Full Article

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Learn more about Thomson Reuters products: